These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19744540)

  • 1. Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation.
    Flück CE; Mullis PE; Pandey AV
    Mol Cell Endocrinol; 2009 Dec; 313(1-2):17-22. PubMed ID: 19744540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
    Flück CE; Nicolo C; Pandey AV
    Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical analysis of mutations in P450 oxidoreductase.
    Pandey AV
    Biochem Soc Trans; 2006 Dec; 34(Pt 6):1186-91. PubMed ID: 17073782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NADPH-cytochrome P450 oxidoreductase from the chicken (Gallus gallus): sequence characterization, functional expression and kinetic study.
    Zhou X; Li M; Sheng C; Qiu X
    Comp Biochem Physiol C Toxicol Pharmacol; 2011 Jan; 153(1):53-9. PubMed ID: 20728568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of mutant cytochrome P450 reductase activity by external flavin.
    Nicolo C; Flück CE; Mullis PE; Pandey AV
    Mol Cell Endocrinol; 2010 Jun; 321(2):245-52. PubMed ID: 20188793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exhaustive computational search of ionic-charge clusters that mediate interactions between mammalian cytochrome P450 (CYP) and P450-oxidoreductase (POR) proteins.
    Zawaira A; Gallotta M; Beeton-Kempen N; Coulson L; Marais P; Kuttel M; Blackburn J
    Comput Biol Chem; 2010 Feb; 34(1):42-52. PubMed ID: 19939736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA-interference approach to study functions of NADPH : cytochrome P450 oxidoreductase in human hepatocytes.
    Feidt DM; Klein K; Nüssler A; Zanger UM
    Chem Biodivers; 2009 Nov; 6(11):2084-91. PubMed ID: 19937842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A second FMN binding site in yeast NADPH-cytochrome P450 reductase suggests a mechanism of electron transfer by diflavin reductases.
    Lamb DC; Kim Y; Yermalitskaya LV; Yermalitsky VN; Lepesheva GI; Kelly SL; Waterman MR; Podust LM
    Structure; 2006 Jan; 14(1):51-61. PubMed ID: 16407065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.
    Li W; Tang Y; Liu H; Cheng J; Zhu W; Jiang H
    Proteins; 2008 May; 71(2):938-49. PubMed ID: 18004755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of human CYP19A1 activity by mutant NADPH P450 oxidoreductase.
    Pandey AV; Kempná P; Hofer G; Mullis PE; Flück CE
    Mol Endocrinol; 2007 Oct; 21(10):2579-95. PubMed ID: 17595315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational dynamics and the energetics of protein--ligand interactions: role of interdomain loop in human cytochrome P450 reductase.
    Grunau A; Geraki K; Grossmann JG; Gutierrez A
    Biochemistry; 2007 Jul; 46(28):8244-55. PubMed ID: 17580970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P450 oxidoreductase: genotyping, expression, purification of recombinant protein, and activity assessments of wild-type and mutant protein.
    Agrawal V; Miller WL
    Methods Mol Biol; 2013; 987():225-37. PubMed ID: 23475681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of genetic variation on human cytochrome p450 reductase-mediated paraquat cytotoxicity.
    Han JF; Wang SL; He XY; Liu CY; Hong JY
    Toxicol Sci; 2006 May; 91(1):42-8. PubMed ID: 16495354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antley-Bixler syndrome or POR deficiency?].
    Tomková M; Marohnic CC; Baxová A; Martásek P
    Cas Lek Cesk; 2008; 147(5):261-5. PubMed ID: 18630181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class-dependent sequence alignment strategy improves the structural and functional modeling of P450s.
    Baudry J; Rupasinghe S; Schuler MA
    Protein Eng Des Sel; 2006 Aug; 19(8):345-53. PubMed ID: 16777908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome.
    Flück CE; Tajima T; Pandey AV; Arlt W; Okuhara K; Verge CF; Jabs EW; Mendonça BB; Fujieda K; Miller WL
    Nat Genet; 2004 Mar; 36(3):228-30. PubMed ID: 14758361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of the NADPH cytochrome P450 reductase gene (CPR) from Candida bombicola.
    Van Bogaert IN; Develter D; Soetaert W; Vandamme EJ
    FEMS Yeast Res; 2007 Sep; 7(6):922-8. PubMed ID: 17559413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of P450 oxidoreductase: implications in drug metabolism and therapy.
    Hu L; Zhuo W; He YJ; Zhou HH; Fan L
    Pharmacogenet Genomics; 2012 Nov; 22(11):812-9. PubMed ID: 23047293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rescue of cytochrome P450 oxidoreductase (Por) mouse mutants reveals functions in vasculogenesis, brain and limb patterning linked to retinoic acid homeostasis.
    Ribes V; Otto DM; Dickmann L; Schmidt K; Schuhbaur B; Henderson C; Blomhoff R; Wolf CR; Tickle C; Dollé P
    Dev Biol; 2007 Mar; 303(1):66-81. PubMed ID: 17126317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of NADPH-cytochrome P450 oxidoreductases (POR) in Apiales - POR 1 is missing.
    Andersen TB; Hansen NB; Laursen T; Weitzel C; Simonsen HT
    Mol Phylogenet Evol; 2016 May; 98():21-8. PubMed ID: 26854662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.